Boehringer and DeveloGen collaborate on diabetes and metabolic syndrome treatments
Boehringer Ingelheim and DeveloGen AG have agreed an asset sale and purchase and collaboration agreement in the field of diabetes, obesity, the metabolic syndrome and other insulin resistance associated disorders.
Boehringer Ingelheim and DeveloGen AG have agreed an asset sale and purchase and collaboration agreement in the field of diabetes, obesity, the metabolic syndrome and other insulin resistance associated disorders.
Under the terms of the agreement, Goettingen gased DeveloGen will receive an upfront payment of Euro 7m, with the opportunity to earn additional deferred payments.. DeveloGen will also receive research payments to support further discovery and development efforts.
Using functional genomics, DeveloGen has identified and validated a relevant target directly addressing insulin resistance.
Initial compounds, that have been discovered and optimised by DeveloGen, have proven to be effective in preclinical models of type 2 diabetes and obesity, improving carbohydrate and lipid metabolism while reducing weight gain and preserving beta cell function."
Boehringer Ingelheim has a late stage pipeline of innovative metabolic disease programmes. Prof. Andreas Barner, head of Corporate Board Division Pharma Research, Development and Medicine, said DeveloGen's programme would complement and expand Boehringer Ingelheim's current diabetes pipeline beyond its two late stage development compounds targeting DPP-4 and SGLT-2.